In one paragraphArticle in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Andrew R Schroeder *Department of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-9037-7463 Fangming Zhu *Department of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-7805-6969 Xianyou XiaDepartment of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0009-0006-9363-9816 Hui HuDepartment of Microbiology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-2915-7189 Funding
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1MMEDICAL SCIENTIST TRAINING PROGRAMT32GM008361 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI YACOUBIAN, TALENE ALENE · 1992 to 2024
$16.8MIMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MRegulation of Tfh cell differentiation and humoral immunityR01AI130232 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HU, HUI · 2017 to 2021
$2.6MTranscriptional Regulation of CD4+ T Cell Differentiation and Diversified MemoryR01AI177467 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Hui Hu · 2023 to 2026
$2.0MTranscriptional Regulation of CD4+ T Cell Differentiation and Diversified MemoryR56AI167986 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HU, HUI · 2023 to 2023
$325kNHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS P30 AI027767NIAID NIH HHS R01 AI130232NIAID NIH HHS R01 AI177467NIAID NIH HHS R56 AI167986NIAID NIH HHS T32 AI007051NIDA NIH HHS 75N95020D00005NIGMS NIH HHS T32 GM008361NIH HHS 75N93023D00005NIH HHS 75N99020D00005NIH HHS AI130232NIH HHS AI167986NIH HHS AI177467NIH HHS T32AI007051NIH HHS T32GM008361University of Alabama at Birmingham Center for AIDS Research P30AI027767-26
6 · The paper itselfAbstract
CD4+ T cells differentiate into T follicular helper (Tfh) and non-Tfh cells, helping regulate humoral and cellular responses. Here, we show that in robust CD4+ T cell responses, all early CXCR5+CD4+ T cells expressed CD25, and STAT5, which inhibits Tfh cell differentiation, was crucial for both non-Tfh and Tfh responses. We found that after T cell activation, the transient increase in BACH2 protein levels temporarily suppressed STAT5-mediated Blimp1 induction, licensing early CXCR5+CD25+CD4+ T cells to proliferate to STAT5 signaling without being suppressed for the subsequent Tfh cell differentiation. Furthermore, depending on the immunization route, location, and antigen dose, BACH2 exerted bidirectional regulation on the differentiation of CXCR5- versus CXCR5+ CD4+ T cells throughout the body. Our findings suggest BACH2 orchestrates systemic immunity, offering insights for harnessing CD4+ T cell responses in vaccines and treatments.
Indexed as
Basic-Leucine Zipper Transcription FactorsCD4-Positive T-LymphocytesCell DifferentiationReceptors, CXCR5AnimalsInterleukin-2 Receptor alpha SubunitLymphocyte ActivationMiceMice, Inbred C57BLSignal TransductionSTAT5 Transcription FactorBach2 protein, mouseBasic-Leucine Zipper Transcription FactorsCXCR5 protein, mouseInterleukin-2 Receptor alpha SubunitReceptors, CXCR5STAT5 Transcription Factor
Identifiers
PMID42257674
PMCPMC13629307
What OpenQuestion holds
Textmetadata
Read underepoch 390